NCT06865339 2026-04-13
TRIPL
Montefiore Medical Center
Phase 2 Recruiting
Clinical Trials
16 trialsNCT06738160 2026-03-20
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Fudan University
Phase 2 Recruiting
NCT07388771 2026-03-19
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
Tongji Hospital
Recruiting
NCT05798845 2026-03-11
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Recruiting
NCT07082179 2026-02-11
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT06576635 2026-01-20
LUNG-05
University of Illinois at Chicago
Phase NA Recruiting
NCT07330037 2026-01-09
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07169552 2025-12-17
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
HC Biopharma Inc.
Phase 2 Recruiting
NCT07247227 2025-11-25
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
Peking Union Medical College
Phase NA Recruiting
NCT07181499 2025-09-30
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Betta Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT07198217 2025-09-30
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
Zibo Municipal Hospital
Phase 2 Recruiting
NCT06864624 2025-07-25
WU-KONG20
Tang-Du Hospital
Phase 2 Recruiting
NCT07085182 2025-07-25
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
Zibo Municipal Hospital
Phase 2 Recruiting
NCT06754644 2025-06-10
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06940401 2025-05-14
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2 Recruiting
NCT05994131 2025-04-30
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting